Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Polyclonal Antibodies in Simultaneous Pancreas Kidney Transplant Recipients: Single-centre, Prospective, Observational Study

NCT03470961 is registered in ClinicalTrials.gov with Tianjin First Central Hospital as lead sponsor.

NCT NCT03470961
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03470961 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Polyclonal Antibodies in Simultaneous Pancreas Kidney Transplant Recipients: Single-centre, Prospective, Observational Study
Lead sponsor
Tianjin First Central Hospital
Phase
Phase 4
Overall status
Unknown status
Start date
March 1, 2018
Completion date
March 1, 2021
Enrollment
45 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ckd (chronic kidney disease) stage 5t, diabetes mellitus, simultaneous pancreas kidney transplantation